Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) Capital Leases (2022 - 2026)

Lexeo Therapeutics' Capital Leases history spans 2 years, with the latest figure at $1.2 million for Q4 2023.

  • On a quarterly basis, Capital Leases fell 24.33% to $1.2 million in Q4 2023 year-over-year; TTM through Dec 2023 was $1.2 million, a 24.33% decrease, with the full-year FY2023 number at $1.2 million, down 24.33% from a year prior.
  • Capital Leases hit $1.2 million in Q4 2023 for Lexeo Therapeutics, down from $1.4 million in the prior quarter.
  • Over the last five years, Capital Leases for LXEO hit a ceiling of $1.6 million in Q4 2022 and a floor of $1.2 million in Q4 2023.